Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-12-04 in 15w | $PFE | Phase 1 | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant… NCT07231991 |
| 2026-12-04 in 15w | $REGN | Phase 1 | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe… NCT06452771 |
| 2026-12-09 in 16w | $INCY | Phase 1 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent… NCT07049575 |
| 2026-12-14 in 17w | $AMGN | Phase 3 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) NCT06430866 |
| 2026-12-17 in 17w | $AMGN | Phase 1 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C… NCT04185883 |
| 2026-12-26 in 18w | $INCY | Phase 3 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in… NCT06212999 |
| 2026-12-29 in 19w | $ALNY | Phase 1 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers NCT07295717 |
| 2026-12-29 in 19w | $REGN | Phase 2 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult… NCT07477704 |
| 2026-12-30 in 19w | $VRTX | Phase 2 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With… NCT06794996 |
| 2026-12-31 in 19w | $SRPT | Phase 1 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy NCT06138743 |
| 2026-12-31 in 19w | $AMGN | Phase 1 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab… NCT03319940 |
| 2026-12-31 in 19w | $ARGX | Phase 1 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers NCT07377396 |
| 2026-12-31 in 19w | $VIR | Phase 3 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection NCT06903338 |
| 2026-12-31 in 19w | $BPMC | Phase 2 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous… NCT06931405 |
| 2027-01-01 in 19w | $INCY | Phase 1 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic… NCT06179160 |
| 2027-01-04 in 20w | $INCY | Phase 1 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When… NCT07559396 |
| 2027-01-06 in 20w | $INCY | Phase 1 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent… NCT06843408 |
| 2027-01-06 in 20w | $REGN | Phase 1 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With… NCT05259709 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2… NCT06858839 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type… NCT06858878 |
| 2027-01-25 in 23w | $VRTX | Phase 3 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in… NCT06696443 |
| 2027-01-30 in 23w | $VRTX | Phase 4 | Evaluation of Pain Treatment After Total Knee Arthroplasty NCT07538570 |
| 2027-02-02 in 24w | $BIIB | Phase 1 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in… NCT07225517 |
| 2027-02-02 in 24w | $VRTX | Phase 1 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1… NCT06185764 |
| 2027-02-09 in 25w | $REGN | Phase 2 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With… NCT07175428 |